Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity

Abstract

This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.

1 .- 14 . (canceled)  
   
   
       15 . A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising an agonist of the GLP-1 receptor wherein the agonist is a peptide that is resistant to cleavage by the enzyme dipeptidyl-peptidase IV.  
   
   
       16 . The method of  claim 15  wherein the composition further comprises a pharmaceutically acceptable buffer.  
   
   
       17 . The method of  claim 16  wherein the composition further comprises an anti-microbial agent.  
   
   
       18 . The method of  claim 17  wherein the anti-microbial agent is selected from phenol and meta-cresol.  
   
   
       19 . The method of  claim 17  further comprising an isotonicity agent.  
   
   
       20 . The method of  claim 15  wherein the composition is administered by a non-parenteral route selected from the group consisting of: oral, rectal, nasal, and lower respiratory.  
   
   
       21 . The method of  claim 15  wherein the composition is a controlled release preparation  
   
   
       22 . The method of  claim 21  wherein the controlled release preparation comprises particles of a polymeric material.